Table 1

Summary characteristics of the included studies

All studiesStudies in patients with high cardiovascular risk
Total number of studies39 (100%)4 (100%)
No. of patients in all studies49921230
Publication year, median (range)1996 (1974–2014)2013 (1992–2014)
Publication year <200024 (62%)1 (25%)
Multicentre studies9 (23%)0 (0%)
Study size, median (IQR)84 (54–129)251 (210–406)
Patient age, median (IQR)54 (51–61)66 (63–67)
Male sex, median (IQR)62 (25–87)77 (66–88)
Follow-up*
 0.5–1 year7 (18%)3 (75%)
 >1–3 years21 (54%)1 (25%)
 >3 years11 (28%)0 (0%)
Colchicine treatment (mg/day)
 ≤127 (69%)3 (75%)
 >112 (31%)1 (25%)
Control treatment, n (%)
 Active treatment8 (21%)0 (0%)
 Inactive, placebo31 (79%)4 (100%)
Clinical setting
 CVD, arteriosclerotic3 (8%)3 (75%)
 CVD, other1 (3%)1 (25%)
 Hepatobiliary disease25 (64%)0 (0%)
 Other10 (26%)0 (0%)
Cardiovascular risk profile
 Primary prevention0 (0%)0 (0%)
 Secondary prevention4 (10%)4 (100%)
 Not specified35 (90%)0 (0%)
Risk of bias (high, unclear, low)
 Randomisation3%/59%/38%0%/25%/75%
 Allocation concealment0%/72%/28%0%/75%/25%
 Blinding of patients and personnel18%/13%/69%25%/0%/75%
 Blinding of outcome assessment0%/79%/21%0%/25%/75%
 Incomplete outcome data41%/38%/21%0%/50%/50%
 Selective reporting13%/84%/3%0%/100%/0%
  • Number of studies (% of column total) if not stated otherwise.

  • *Longest follow-up period for an outcome that was used in this systematic review.

  • CVD, cardiovascular disease.